THE ARISING · Longevity & Healthspan
An experimental antibody reduced lean-mass loss in a semaglutide trial
A randomized phase 2 trial found a difference on body-composition scans. It did not establish that participants became stronger or moved better.
When someone loses weight, the number on the scale doesn't show how much came from fat and how much came from lean tissue. The COURAGE trial, published in The Lancet, asked whether adding trevogrumab, an experimental antibody that blocks the muscle-growth regulator myostatin, could reduce lean-mass loss in adults with obesity taking semaglutide.
The two-part trial enrolled 975 adults. In the 26-week part, lean mass fell by 6.6% on average in the semaglutide-plus-placebo group. Adding trevogrumab reduced that loss by an estimated 3.1 percentage points in one dose group (95% confidence interval 1.9 to 4.3) and 2.7 points in the other (1.5 to 4.0). Both doses should be regarded as trial comparisons, not treatment or dosing recommendations. A separate 52-week part used different doses: its higher dose reduced lean-mass loss relative to placebo, while the confidence interval for the lower dose included no difference.
A separate group also received a second experimental antibody, garetosmab. That combination preserved more lean mass at 26 weeks but had a worse safety and tolerability profile. Fourteen of 149 people had serious adverse events and 48 discontinued treatment. Two participants in that group died; the investigators did not identify a causal link to treatment. The combination's results should not be conflated with those for trevogrumab alone.
The trial was funded by Regeneron, trevogrumab's developer. Its central finding is about measured body composition. Lean mass and muscle strength are not interchangeable: retaining more lean tissue on a scan doesn't tell us whether participants found it easier to climb stairs, carry groceries or maintain independence. Those are outcomes a later trial would have to measure directly.
This phase 2 result is not a reason to change a prescription or seek the experimental combination.
Primary source: COURAGE trial, *The Lancet*, November 11, 2026